Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study - Trial NCT06404840
Access comprehensive clinical trial information for NCT06404840 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tianjin Medical University Cancer Institute and Hospital
Timeline & Enrollment
Phase 2
May 06, 2022
May 31, 2026
Primary Outcome
AEs
Summary
Patients with PCLM account for the majority of our department's pancreatic cancer cases and
 often have limited surgical options due to the aggressive nature of their tumors. For those
 with good performance status (ECOG PS 0-1), NCCN recommends gemcitabine + nab-paclitaxel
 (AG). Though nimotuzumab combined with gemcitabine improves survival, there remains scarce
 clinical data regarding its efficacy in conjunction with AG for treating PCLM. This study
 aims to evaluate the safety and efficacy of incorporating nimotuzumab with AG for PCLM.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06404840
Non-Device Trial